skip to content »

Breast Center - Osborne Schiff Lab

Houston, Texas

A BCM research lab.
Osborne Schiff Lab - Lester and Sue Smith Breast Center
not shown on screen


Selected Publications

Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R.
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Cancer Res. 2008 Sep 15;68(18):7493-501.

Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R.
Molecular profiles of progesterone receptor loss in human breast tumors.
Breast Cancer Res Treat. 2008 Apr 19.

Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R.
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
Cancer Res. 2008 Feb 1;68(3):826-33.

Arpino G, Wiechmann L, Osborne CK, Schiff R.
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
Endocr Rev. 2008 Apr;29(2):217-33.

Lopez-Tarruella S, Schiff R.
The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm.
Clin Cancer Res. 2007 Dec 1;13(23):6921-5.

Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, Sevick-Muraca EM.
Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
J Nucl Med. 2007 Sep;48(9):1501-10.

Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R.
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
J Natl Cancer Inst. 2007 May 2;99(9):694-705.

Massarweh S, Schiff R.
Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
Clin Cancer Res. 2007 Apr 1;13(7):1950-4.

Massarweh S, Schiff R.
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S15-24.

Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R.
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Cancer Res. 2006 Aug 15;66(16):8266-73.

Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV.
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
Breast Cancer Res Treat. 2006 Aug;98(3):315-27.

Schiff R, Lee AV.
Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?
Nat Clin Pract Oncol. 2006 Mar;3(3):134-5. [Full Text]

Harrington WR, Kim SH, Funk CC, Madak-Erdogan Z, Schiff R, Katzenellenbogen JA, Katzenellenbogen BS.
Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action.
Mol Endocrinol. 2006 Mar;20(3):491-502.

Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK.
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:10-20.

Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG.
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
Breast. 2005 Dec;14(6):458-65.

Cui X, Schiff R, Arpino G, Osborne CK, Lee AV.
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
J Clin Oncol. 2005 Oct 20;23(30):7721-35.

Schiff R, Osborne CK.
Endocrinology and hormone therapy in breast cancer: new insight into estrogen-alpha function and its implication for endocrine therapy resistance in breast cancer.
Breast Cancer Res. 2005 7;(5):205-11.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

Dowsett M, Johnston S, Martin LA, Salter J, Hills M, Detre S, Gutierrez MC, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Smith I.
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S113-7.

Osborne CK, Schiff R.
Aromatase inhibitors: future directions.
J Steroid Biochem Mol Biol. 2005 May;95(1-5):183-7.

Osborne CK, Schiff R.
Estrogen-receptor biology: continuing progress and therapeutic implications.
J Clin Oncol. 2005 Mar 10;23(8):1616-22.

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M.
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
J Clin Oncol. 2005 Apr 10;23(11):2469-76.

Osborne CK, Shou J, Massarweh S, Schiff R.
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):865s-70s.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.

Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK.
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.
Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):331S-6S.

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R.
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
J Natl Cancer Inst. 2003 Mar 5;95(5):353-61.

E-mail this page to a friend